Cadence Bank Sells 61 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Cadence Bank trimmed its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 1.5% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 3,945 shares of the biotechnology company’s stock after selling 61 shares during the quarter. Cadence Bank’s holdings in United Therapeutics were worth $1,414,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in UTHR. LSV Asset Management grew its position in United Therapeutics by 82.5% in the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock valued at $307,837,000 after acquiring an additional 436,851 shares during the last quarter. Swedbank AB bought a new position in shares of United Therapeutics in the first quarter worth about $97,316,000. FMR LLC grew its holdings in shares of United Therapeutics by 41.1% in the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after purchasing an additional 314,004 shares during the last quarter. Assetmark Inc. increased its stake in United Therapeutics by 56.9% in the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock worth $150,492,000 after buying an additional 152,249 shares during the period. Finally, Pacer Advisors Inc. lifted its holdings in United Therapeutics by 19.6% during the 2nd quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock valued at $178,972,000 after buying an additional 92,240 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Trading Up 0.3 %

NASDAQ UTHR opened at $378.13 on Thursday. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $417.82. The stock has a 50-day moving average of $366.18 and a 200 day moving average of $333.84. The stock has a market capitalization of $16.88 billion, a price-to-earnings ratio of 16.61, a PEG ratio of 1.07 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business’s revenue was up 22.9% on a year-over-year basis. During the same quarter last year, the firm posted $5.38 EPS. Equities analysts predict that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on UTHR shares. Bank of America reduced their target price on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a research report on Thursday, August 1st. Oppenheimer lifted their target price on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. The Goldman Sachs Group increased their price target on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research report on Friday, November 1st. Argus upped their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, TD Cowen lifted their target price on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $370.86.

Insider Buying and Selling at United Therapeutics

In related news, EVP Paul A. Mahon sold 7,700 shares of the firm’s stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $367.36, for a total value of $2,828,672.00. Following the transaction, the executive vice president now directly owns 36,710 shares of the company’s stock, valued at approximately $13,485,785.60. This trade represents a 17.34 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO James Edgemond sold 7,785 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total value of $2,821,050.45. Following the sale, the chief financial officer now owns 2,615 shares of the company’s stock, valued at approximately $947,597.55. This trade represents a 74.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 127,227 shares of company stock valued at $47,398,820 over the last ninety days. Corporate insiders own 11.90% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.